Laboratory Services News & Publications
Important Testing Notification
Please see important testing notification regarding potential for false-positive Norovirus with Gastrointestinal Infection Array (GIIA) Testing.
Testing Updates
October 21, 2025
Important Test Announcement:
Updates to Thyroid Profile Testing Options
October 20, 2025
Important Test Announcement: Updates to Glucagon Testing
October 13, 2025
Important Test Announcement: Drugs of Abuse, Urine Tests Update
October 13, 2025
Important Test Announcement: Fentanyl, Urine
September 16, 2025
Important Test Announcement: Clobazam and Metabolite, Quantitative, Serum or Plasma Update
September 2, 2025
Important Test Announcement: Oncology Chromosomal Microarray Analysis
September 2, 2025
Important Test Announcement: Cortisol for Dexamethasone Suppression and Vancomycin Random for Continuous Infusion
August 26, 2025
Important Test Announcement: Copeptin proAVP, Plasma
August 12, 2025
Important Test Announcement: Updates to Amikacin, Pre-Dose and Amikacin, Post-Dose
August 11, 2025
Important Test Announcement: Fecal Calprotectin New Methodology
July 29, 2025
Important Test Announcement: Updates to Measles Virus By PCR with Reflex and Measles (Rubeola) Antibody, IGM Testing
June 30, 2025
Important Test Announcement: Influenza A H5, Avian By PCR
May 27, 2025
Important Test Announcement: Phenylalanine/Tyrosine, Plasma and Phenylalanine/Tyrosine, Dried Blood Spot & Maple Syrup Urine Disease (MSUD) Monitor, Dried Blood Spot
April 8, 2025
New Reference Ranges
October 20, 2025
Changes in reference range for Glucagon Testing
August 12, 2025
Changes in reference range for Amikacin (Pre and Post dose)
July 8, 2025
Changes in reference range for Reticulocyte Count
October 15, 2024
Changes in reference range for Quantitative Factor XIII
Laboratory Services Newsletters
2025 Newsletters
2024 Newsletters
Sexually Transmitted Infection Testing Resources
Nationwide Children’s Laboratory Services provides resources for health care professionals, including a Sexually Transmitted Infections Practice Tool. Visit Clinical Tools for a complete list.
Included in the current STI Practice Tool are recommendations from the Centers for Disease Control and Prevention (CDC) regarding “opt-out” testing policies.
According to CDC recommendations, providers might consider opt-out chlamydia and gonorrhea screening (i.e., the patient is notified that testing will be performed unless the patient declines, regardless of reported sexual activity) for adolescent and young adult females during clinical encounters. Cost-effectiveness analyses indicate that opt-out chlamydia screening among adolescent and young adult females might substantially increase screening, be cost saving and identify infections among patients who do not disclose sexual behavior.
Nationwide Children’s has provided sample opt-out letters that providers may download and customize for patient/parent communication:
Patient Letter (Customizable)
Download:
Parent Letter (Customizable)
Download: